ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources

Robert E. Henkin, John D. Del Rowe, Perry W. Grigsby, Alan C. Hartford, Hossein Jadvar, Roger M. MacKlis, J. Anthony Parker, Jeffrey Y.C. Wong, Seth A. Rosenthal

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

This guideline is intended to guide appropriately trained and licensed physicians performing therapy with unsealed radiopharmaceutical sources. Adherence to this guideline should help to maximize the efficacious use of these procedures, maintain safe conditions, and ensure compliance with applicable regulations. The topics dealt with in this guideline include indications for the use of iodine-131, both for the treatment of hyperthyroidism and thyroid carcinoma. In addition, indications for other less common procedures include those for the use of phosphorous-32 in its liquid and colloidal forms, strontium-89, samarium-153, and the use of Y-90 antibodies.

Original languageEnglish
Pages (from-to)e72-e80
JournalClinical nuclear medicine
Volume36
Issue number8
DOIs
StatePublished - Aug 1 2011

Keywords

  • iodine-131
  • phosphorous-32
  • radionuclide therapy
  • radiopharmaceutical
  • samarium-153
  • strontium-89
  • unsealed sources
  • yttrium-90

Fingerprint

Dive into the research topics of 'ACR-ASTRO practice guideline for the performance of therapy with unsealed radiopharmaceutical sources'. Together they form a unique fingerprint.

Cite this